Table 4 The antimicrobial susceptibility profiles of Salmonella isolates with different serotypes
Antimicrobial agent | No. of resistant isolates by serotypes (resistant rate, %) | |||||
|---|---|---|---|---|---|---|
Typhimurium (n = 85) | Enteritidis (n = 29) | London (n = 5) | Senftenberg (n = 8) | Others (n = 70) | Total (n = 197) | |
Penicillins | ||||||
 ampicillin | 81 (95.3) | 22 (75.9) | 2 (40.0) | 0 (0.0) | 34 (48.6) | 139 (70.6) |
 piperacillin | 74 (87.1) | 21 (72.4) | 2 (40.0) | 0 (0.0) | 30 (42.9) | 127 (64.5) |
β-lactam/β-lactamase inhibitors | ||||||
 ampicillin/ sulbactam | 9 (10.6) | 7 (24.1) | 0 (0.0) | 1 (12.5) | 6 (8.6) | 23 (11.7) |
Cephems | ||||||
 cefazolin | 50 (58.8) | 16 (55.2) | 1 (20.0) | 1 (12.5) | 19 (27.1) | 87 (44.2) |
 cefepime | 23 (27.1) | 5 (17.2) | 0 (0.0) | 0 (0.0) | 9 (12.9) | 37 (18.8) |
 cefotaxime | 40 (47.1) | 8 (27.6) | 0 (0.0) | 1 (12.5) | 15 (21.4) | 64 (32.5) |
 ceftriaxone | 42 (49.4) | 9 (31.0) | 0 (0.0) | 1 (12.5) | 14 (20.0) | 66 (33.5) |
 cefoxitin | 3 (3.5) | 2 (6.9) | 0 (0.0) | 1 (12.5) | 1 (1.4) | 7 (3.6) |
 ceftazidime | 13 (15.3) | 3 (10.3) | 0 (0.0) | 0 (0.0) | 7 (10.0) | 23 (11.7) |
Monobactams | ||||||
 aztreonam | 23 (27.1) | 3 (10.3) | 0 (0.0) | 0 (0.0) | 9 (12.9) | 35 (17.8) |
Aminoglycosides | ||||||
 gentamicin | 22 (25.9) | 0 (0.0) | 3 (60.0) | 0 (0.0) | 13 (18.6) | 38 (19.3) |
 amikacin | 2 (2.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (1.0) |
 streptomycin | 57 (67.1) | 20 (69.0) | 2 (40.0) | 1 (12.5) | 27 (38.6) | 107 (54.3) |
Carbapenems | ||||||
 imipenem | 3 (3.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.4) | 4 (2.0) |
 meropenem | 2 (2.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (1.0) |
Tetracyclines | ||||||
 tetracycline | 81 (95.3) | 3 (10.3) | 2 (40.0) | 0 (0.0) | 39 (55.7) | 125 (63.5) |
Quinolones and Fluoroquinolones | ||||||
 ciprofloxacin | 7 (8.2) | 2 (6.9) | 2 (40.0) | 0 (0.0) | 8 (11.4) | 19 (9.6) |
 levofloxacin | 5 (5.9) | 1 (3.4) | 0 (0.0) | 0 (0.0) | 6 (8.6) | 12 (6.1) |
 norfloxacin | 7 (8.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (4.3) | 10 (5.1) |
 nalidixic acid | 26 (30.6) | 27 (93.1) | 3 (60.0) | 0 (0.0) | 18 (25.7) | 74 (37.6) |
Folate pathway inhibitors | ||||||
 sulphamethoxazole/trimethoprim | 42 (49.4) | 4 (13.8) | 2 (40.0) | 1 (12.5) | 26 (37.1) | 75 (38.1) |
 trimethoprim | 38 (44.7) | 3 (10.3) | 2 (40.0) | 0 (0.0) | 22 (31.4) | 65 (33.0) |
Phenicols | ||||||
 Chloramphenicol | 41 (48.2) | 2 (6.9) | 1 (20.0) | 0 (0.0) | 21 (30.0) | 65 (33.0) |
Nitrofurans | ||||||
 nitrofurantoin | 2 (2.4) | 11 (37.9) | 0 (0.0) | 0 (0.0) | 8 (11.4) | 21 (10.7) |
MAR index | ||||||
 <0.08 | 0 (0.0) | 3 (10.3) | 2 (40.0) | 6 (72.5) | 23 (32.9) | 34 (17.3) |
 0.08- | 3 (3.5) | 3 (10.3) | 0 (0.0) | 1 (12.5) | 5 (7.1) | 12 (6.1) |
 0.13- | 5 (5.9) | 1 (3.4) | 1 (20.0) | 0 (0.0) | 3 (4.3) | 10 (5.1) |
 0.17- | 10 (11.8) | 2 (6.9) | 0 (0.0) | 1 (12.5) | 5 (7.1) | 18 (9.1) |
 ≥0.21 | 67 (78.8) | 20 (69.0) | 2 (40.0) | 0 (0.0) | 34 (48.6) | 123 (62.4) |